Hydroxychloroquine treatment on SARS-CoV-2 receptor ACE2, TMPRSS2 and NRP1 expression in human primary pterygium and conjunctival cells

Yao, Yao; Ma, Di; Xu, Yanxuan; Yuan, Xiang‐Ling; Liang, Ji‐Zhao; Chen, Shao-Lang; Jhanji, Vishal; Ng, Tsz Kin

doi:10.1016/j.exer.2021.108864

Cited by 4 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proliferation of HUVECs with EPO treatment was evaluated by the Cell Counting Kit-8 (CCK-8) assay (Sigma-Aldrich, St. Louis, MO), according to our previously established protocol. 18 Briefly, 1000 cells/well (3 wells for each treatment group) were seeded on the 96-well plates 1 day before the start of the treatment, and treated with 10 U/mL human recombinant EPO protein (Abcam, Cambridge, United Kingdom) for 5 days. The cells in basal medium without EPO treatment were considered as control.…”

Section: Methodsmentioning

confidence: 99%

Reduction of Laser-Induced Choroidal Neovascularization in Mice With Erythropoietin RNA Interference

Chen

Huang

et al. 2022

Trans. Vis. Sci. Tech.

Self Cite

View full text Add to dashboard Cite

Purpose The purpose of this study was to evaluate the pathological involvement of erythropoietin (EPO) in experimental choroidal neovascularization (CNV) and its association with neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) in the Chinese population. Methods Treatment effect of recombinant EPO protein were assessed by human umbilical vein endothelial cell (HUVEC) proliferation, migration, and tube formation, and ex vivo choroid-sprouting ability. The effect of intravitreal injection of Epo siRNA against neovascularization was evaluated in the laser-induced CNV mouse model. In addition, the association of EPO variants with neovascular AMD and PCV was determined. Results Exogenous supplementation of EPO significantly enhanced the migration and tube formation of HUVECs and promoted ex vivo choroid sprouting in mouse retinal pigment epithelium (RPE)-choroid-sclera complex culture. In the experimental CNV mouse model, Epo expression was found to be significantly upregulated by 3.5-folds in RPE-choroid-sclera complex at day 10 after laser induction as compared to the baseline. Immunofluorescence analysis showed that Epo was mainly expressed around the vascular endothelial cells in the RPE-choroid-sclera complex. Intravitreal injection of siRNA targeting Epo reduced 40% Epo expression and 40% CNV lesion areas as compared to the scramble control. However, EPO variants were not associated with neovascular AMD nor PCV in the Chinese population. Conclusions This study revealed the promotion of human endothelial cell tube formation in vitro and choroid sprouting ex vivo by EPO, and the reduction of laser-induced CNV in vivo by Epo RNA interference . Translational Relevance Targeting EPO could be a potential additional treatment for CNV-related diseases.

show abstract

Section: Methodsmentioning

confidence: 99%

Reduction of Laser-Induced Choroidal Neovascularization in Mice With Erythropoietin RNA Interference

Chen

Huang

et al. 2022

Trans. Vis. Sci. Tech.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The use of hydroxychloroquine has been seen to reduce ACE2 expression in the conjunctiva and pterygium. [ 36 ]…”

Section: Potential Mechanism Of Coronavirus Infection Disease-19 Ante...mentioning

confidence: 99%

Manifestations of coronavirus infection disease-19 in anterior eye segment: An up-to-date review

Marzoog

2024

Oman Journal of Ophthalmology

View full text Add to dashboard Cite

Coronavirus infection disease-19 (COVID-19) is a worldwide catastrophic emergency that first appeared in late 2019, in Wuhan, China. COVID-19 is a multitropism disease that first affects lung tissue. However, extrapulmonary manifestations have been suspected from the first COVID-19 cases. The ocular signs and symptoms were from the early changes that occur during the course of the disease. Changes in the anterior eye segment have a relatively higher incidence than the posterior eye segment. Of which, conjunctivitis, COVID-19 pharyngioceratoconjuctivitis, iridocyclitis, corneal punctate epitheliopathy, and pathomorphological changes in the physio-anatomy of the anterior eye segment. The potential pathogenesis includes direct penetration of the virus into the eye (conjunctiva, lumbus, and cornea) or due to a systemic pathway through viremia, as well as due to autoimmune antibodies against the ocular structure (immune privilege). The presence of ocular manifestations of the external anterior fibrous layer suggests a mild course of the disease.

show abstract

“…[ 5 8 ] Researchers have discovered the higher expression of ACE2 receptors mostly in the conjunctiva than in the cornea, implying a higher likelihood of SARS-CoV-2 invasion in the conjunctiva instead of the cornea. [ 9 10 ] Recent studies have found the unique pathway of the CD147 receptor can potentially be used to induce viral invasion. [ 11 ]…”

mentioning

confidence: 99%

Assessment of SARS-CoV-2 virus in the tear secretion of conjunctivitis patients during COVID-19 pandemic

Behera

Ghana

Parida

et al. 2022

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: To determine the presence of SARS-CoV-2 virus in the tear secretion of conjunctivitis patients during the COVID-19 pandemic. Methods: This observational, cross-sectional study was conducted in clinically diagnosed patients with conjunctivitis attending the outpatient services of our institute from July 2021 to December 2021. The tear samples were collected from patients using Schirmer’s strips or capillary tubes to detect the presence of SARS-CoV-2 by real-time PCR assay. COVID-19 vaccination and infection status, visual acuity, and clinical features were documented in all cases. Results: A total of 111 patients with symptoms of conjunctivitis were included during the study period. The mean age was 41.1 ± 13.1 years, and the mean duration of symptoms was 7.1 ± 4.4 days, with 74% males. Conjunctival congestion was mild in 69 (62.1%) patients, moderate in 30 (27%) patients, and severe in 12 (10.8%) patients. All except four had superficial punctate keratitis (SPK). Five (4.3%) patients were positive for SARS-CoV-2 RNA in their tear samples. All had mild–moderate conjunctival congestions with variable papiliofollicular reaction and SPKs, superficial hemorrhages were seen in three and pseudomembrane in one patient. They were followed up with telemedicine and three of them developed mild COVID-19-related symptoms and recovered after in-home quarantine. None of them had a previous history of COVID-19 infection and all had received COVID-19 vaccination within 2 weeks to 2 months. Conclusion: SARS-CoV-2 transmission through ocular secretion of conjunctivitis patients cannot be ignored and appropriate COVID-19-preventive behavior should be followed in ocular settings.

show abstract

Hydroxychloroquine treatment on SARS-CoV-2 receptor ACE2, TMPRSS2 and NRP1 expression in human primary pterygium and conjunctival cells

Cited by 4 publications

References 44 publications

Reduction of Laser-Induced Choroidal Neovascularization in Mice With Erythropoietin RNA Interference

Reduction of Laser-Induced Choroidal Neovascularization in Mice With Erythropoietin RNA Interference

Manifestations of coronavirus infection disease-19 in anterior eye segment: An up-to-date review

Assessment of SARS-CoV-2 virus in the tear secretion of conjunctivitis patients during COVID-19 pandemic

Contact Info

Product

Resources

About